Wells Fargo & Co Increases Cooper Companies (COO) Price Target to $305.00

Cooper Companies (NYSE:COO) had its price target boosted by analysts at Wells Fargo & Co from $295.00 to $305.00 in a report released on Friday. The firm currently has an “outperform” rating on the medical device company’s stock. Wells Fargo & Co’s target price would indicate a potential upside of 17.79% from the company’s current price.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets lifted their target price on Cooper Companies from $294.00 to $306.00 and gave the company a “positive” rating in a research report on Friday. KeyCorp cut their target price on Cooper Companies from $298.00 to $296.00 and set an “overweight” rating on the stock in a research report on Friday. Jefferies Financial Group lifted their target price on Cooper Companies to $305.00 and gave the company a “buy” rating in a research report on Friday. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating in a research report on Monday, October 1st. Finally, Raymond James lifted their target price on Cooper Companies from $270.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, September 21st. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $283.30.

Cooper Companies stock traded down $18.09 during mid-day trading on Friday, reaching $258.94. The stock had a trading volume of 5,312 shares, compared to its average volume of 312,680. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 2.58. Cooper Companies has a fifty-two week low of $216.47 and a fifty-two week high of $283.18. The stock has a market capitalization of $13.51 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77.

Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Thursday, December 6th. The medical device company reported $2.87 EPS for the quarter, missing the Zacks’ consensus estimate of $2.96 by ($0.09). Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The firm had revenue of $651.50 million during the quarter, compared to analyst estimates of $645.25 million. During the same period last year, the business posted $2.65 EPS. The company’s revenue was up 16.0% on a year-over-year basis. Research analysts forecast that Cooper Companies will post 11.61 EPS for the current year.

In related news, Director A Thomas Bender sold 7,150 shares of Cooper Companies stock in a transaction on Monday, September 24th. The stock was sold at an average price of $269.36, for a total transaction of $1,925,924.00. Following the sale, the director now directly owns 18,355 shares in the company, valued at $4,944,102.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Randal Golden sold 1,731 shares of Cooper Companies stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $275.86, for a total value of $477,513.66. Following the sale, the vice president now owns 1,154 shares in the company, valued at $318,342.44. The disclosure for this sale can be found here. Insiders have sold 20,691 shares of company stock worth $5,527,869 over the last quarter. 1.60% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. Marshall Wace North America L.P. lifted its holdings in Cooper Companies by 875.3% during the third quarter. Marshall Wace North America L.P. now owns 144,900 shares of the medical device company’s stock worth $40,159,000 after acquiring an additional 130,043 shares during the period. Vanguard Group Inc. lifted its holdings in Cooper Companies by 0.6% during the third quarter. Vanguard Group Inc. now owns 5,041,468 shares of the medical device company’s stock worth $1,397,243,000 after acquiring an additional 31,280 shares during the period. Morgan Stanley lifted its holdings in Cooper Companies by 734.7% during the third quarter. Morgan Stanley now owns 177,658 shares of the medical device company’s stock worth $49,238,000 after acquiring an additional 156,373 shares during the period. Legal & General Group Plc lifted its holdings in Cooper Companies by 9.7% during the third quarter. Legal & General Group Plc now owns 255,020 shares of the medical device company’s stock worth $70,679,000 after acquiring an additional 22,461 shares during the period. Finally, Sawgrass Asset Management LLC lifted its holdings in Cooper Companies by 29.5% during the third quarter. Sawgrass Asset Management LLC now owns 140,077 shares of the medical device company’s stock worth $38,822,000 after acquiring an additional 31,880 shares during the period.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

See Also: Trading Strategy Methods and Types

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply